Hemophiliacs

Trombosis
Hemostatic drug
Haemostatic agent
Hemostatic agent
Haemostatic drug
Hemostatic agents
Haemostatic
Hemostatic

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

Hemophiliacs

Multiple internal therapeutic programs and proven proprietary platforms... An innovator in Drug Discovery and Development significantly improving the speed and efficiency of research and driving clinical trials to success for hemophiliacs.

Hemophiliacs bleeding

Topical solution for hemophiliacs and bleeding treatment. Thrombotargets has developed an antibleeding human protein that will be topically administrated. Know the characteristics of TT-103MH.

Hemophilia treatment

Our pipeline is comprised of innovative drug candidates in the fields of Hemostasis and Thrombosis. Some of these compounds, as our recently Orphan Drug Designated TT-103MH topical antihemorrhagic recombinant protein, are available for licensing out. We also have new anticoagulants, antifibrinolytics, antiplatelet agents, and are working on innovative gene therapies for the treatment of coagulation disorders (Hemophilia, von Willebrand disease, etc).

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.